Table 4.
Patient characteristics after propensity score matching.
| Cetux + Nivo N = 43 |
Rwd-Cetuximab N = 82 |
Rwd-Cpi N = 394 |
Overall p-Value |
|
|---|---|---|---|---|
| Age_at_treatment | 64.0 [57.0;68.0] | 65.0 [59.0;70.0] | 64.5 [58.0;70.0] | 0.692 |
| Gender | 0.106 | |||
| F | 7 (16.3%) | 24 (29.3%) | 77 (19.5%) | |
| M | 36 (83.7%) | 58 (70.7%) | 317 (80.5%) | |
| Race | 0.002 | |||
| White | 38 (88.4%) | 44 (53.7%) | 272 (69.0%) | |
| Black or African American | 3 (7.0%) | 7 (8.5%) | 20 (5.1%) | |
| Others | 2 (4.7%) | 31 (37.8%) | 102 (25.9%) | |
| Ecog PS | 1.00 [1.00;1.00] | 1.00 [0.00;1.00] | 1.00 [1.00;1.00] | 0.504 |
| p16 Status | 0.685 | |||
| non-OP (pos + neg + unknown) | 17 (39.5%) | 41 (50.0%) | 187 (47.5%) | |
| OP (neg + unknown) | 4 (9.3%) | 3 (3.7%) | 25 (6.4%) | |
| OP and unknown primary (pos) | 22 (51.2%) | 38 (46.3%) | 182 (46.2%) | |
| Line of systemic treatment | 2.00 [1.50;2.00] | 2.00 [1.00;2.00] | 2.00 [1.00;2.00] | 0.515 |
| Primary tumor site | 0.851 | |||
| Hypopharynx | 3 (6.98%) | 6 (7.32%) | 34 (8.63%) | |
| Larynx | 6 (14.0%) | 22 (26.8%) | 79 (20.1%) | |
| Oral cavity | 8 (18.6%) | 13 (15.9%) | 74 (18.8%) | |
| Oropharynx | 24 (55.8%) | 38 (46.3%) | 196 (49.7%) | |
| Unknown Primary | 2 (4.65%) | 3 (3.66%) | 11 (2.79%) | |
| Smoking status | 0.751 | |||
| History of smoking | 33 (76.7%) | 66 (80.5%) | 321 (81.5%) | |
| No history of smoking | 10 (23.3%) | 16 (19.5%) | 73 (18.5%) | |
| Survival status | 0.039 | |||
| alive | 12 (27.9%) | 32 (39.0%) | 184 (46.7%) | |
| death | 31 (72.1%) | 50 (61.0%) | 210 (53.3%) | |
|
Length of therapy
(weeks) |
14.0 [8.00;32.9] | 17.7 [9.14;31.5] | 17.9 [9.00;40.1] | 0.713 |
CETUX: cetuximab, NIVO: nivolumab, RWD-Cetuximab: Real World Data-cetuximab monotherapy, RWD-CPI: Real World Data-nivolumab or pembrolizumab checkpoint inhibitor monotherapy, ECOG PS: Eastern Cooperative Oncology Group Performance Status, OP: oropharynx.